About Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine is a company based in Rockville (United States) founded in 2011 was acquired by Janssen Pharmaceutica in May 2018. It operates as a Direct-to-Consumer (D2C), and Professional Services. Johnson & Johnson Innovative Medicine has raised $11 million across 4 funding rounds from investors including Johnson & Johnson Innovative Medicine, HHS and HC2 Holdings. Johnson & Johnson Innovative Medicine offers products and services including INLEXZO™, DARZALEX®, Icotrokinra, and Seltorexant. Johnson & Johnson Innovative Medicine operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Johnson & Johnson And Its Affiliates
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$11 M (USD)
in 4 rounds
-
Latest Funding Round
$2 M (USD), Series A
Nov 15, 2017
- Investors
-
Employee Count
Employee Count
-
Acquired by
Janssen Pharmaceutica
(May 02, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine offers a comprehensive portfolio of products and services, including INLEXZO™, DARZALEX®, Icotrokinra, and Seltorexant. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A system for local bladder cancer drug delivery.
A treatment for high-risk smouldering multiple myeloma.
An oral peptide for plaque psoriasis treatment.
A drug for major depressive disorder treatment.
Funding Insights of Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine has successfully raised a total of $11M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $2 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $2.0M
-
First Round
First Round
(13 Sep 2012)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2017 | Amount | Series A - Johnson & Johnson Innovative Medicine | Valuation |
investors |
|
| Aug, 2016 | Amount | Series A - Johnson & Johnson Innovative Medicine | Valuation | HC2 Holdings |
|
| Feb, 2016 | Amount | Series A - Johnson & Johnson Innovative Medicine | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Johnson & Johnson Innovative Medicine, HHS and HC2 Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed toward infrastructure, life sciences, and media sectors.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Diversified drugs are manufactured for various therapeutic areas.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Johnson & Johnson Innovative Medicine
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Johnson Johnson Innovative Medicine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Johnson & Johnson Innovative Medicine Comparisons
Competitors of Johnson & Johnson Innovative Medicine
Johnson & Johnson Innovative Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Johnson & Johnson Innovative Medicine
Frequently Asked Questions about Johnson & Johnson Innovative Medicine
When was Johnson & Johnson Innovative Medicine founded?
Johnson & Johnson Innovative Medicine was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is Johnson & Johnson Innovative Medicine located?
Johnson & Johnson Innovative Medicine is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Is Johnson & Johnson Innovative Medicine a funded company?
Johnson & Johnson Innovative Medicine is a funded company, having raised a total of $11M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on Sep 13, 2012.
What does Johnson & Johnson Innovative Medicine do?
Johnson Johnson Innovative Medicine is focused on developing transformational medicines in areas such as oncology, immunology, neuroscience, and cardiopulmonary health. Rigorous scientific approaches are employed to create groundbreaking treatments. Patients are supported through clinical trials, patient resources, and innovative drug delivery systems. Global reach and deep expertise are leveraged to reimagine treatment for devastating diseases. Hope and better care are delivered to millions of patients and families worldwide.
Who are the top competitors of Johnson & Johnson Innovative Medicine?
Johnson & Johnson Innovative Medicine's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Johnson & Johnson Innovative Medicine offer?
Johnson & Johnson Innovative Medicine offers INLEXZO™, DARZALEX®, Icotrokinra, and Seltorexant.
Who are Johnson & Johnson Innovative Medicine's investors?
Johnson & Johnson Innovative Medicine has 3 investors. Key investors include Johnson & Johnson Innovative Medicine, HHS, and HC2 Holdings.